Inhibition of Il-17a signaling, which can be achieved by administering Il-17a inhibitors or by depleting specific bacterial taxa in the gut that stimulate the development of Il-17a-producing T cells, therefore has the potential to avoid bacterial overload in the brain and prevent AD progression. This evidence concerns the gene IL17A and Alzheimer disease.